Skip to main content
Fig. 4 | Renal Replacement Therapy

Fig. 4

From: Linagliptin inhibits lipopolysaccharide-stimulated interleukin-6 production, intranuclear p65 expression, and p38 mitogen-activated protein kinase phosphorylation in human umbilical vein endothelial cells

Fig. 4

Interleukin (IL)-6 production after treatment of human umbilical vein endothelial cells (HUVECs) with linagliptin, sitagliptin, caffeine, loxoprofen, and diclofenac sodium. HUVECs were treated with lipopolysaccharide and/or linagliptin, sitagliptin, caffeine, loxoprofen, and diclofenac sodium. IL-6 levels in the supernatants were determined by ELISA after 5 h of treatment. **P < 0.01 vs. control; ## P < 0.01 vs. LPS 1 μg/mL. Lina linagliptin, Sita sitagliptin, Caff caffeine, Loxo loxoprofen, Diclo diclofenac sodium

Back to article page

Renal Replacement Therapy

ISSN: 2059-1381

Contact us